- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06351605
Een registeronderzoek om fotobiomodulatie te beoordelen bij droge leeftijdsgebonden maculaire degeneratie (EUROLIGHT) (EUROLIGHT)
Een registeronderzoek in meerdere centra om de veiligheid en effectiviteit van fotobiomodulatie te beoordelen bij deelnemers met droge leeftijdsgebonden maculaire degeneratie (EUROLIGHT)
The purpose of this registry study is to collect real life data pertaining to the safety and clinical effectiveness of multi-wavelength photobiomodulation (PBM) as provided by the Valeda Light Delivery System in participants with dry age-related macular degeneration (AMD) in routine clinical practice. Data will be collected retrospectively and prospectively.
PBM involves the use of visible light to near infrared light (NIR) (500-1000 nanometers) produced by a laser or a non-coherent light source applied to the surface of the body to activate mitochondrial respiratory chain components, stabilize metabolic function, and promote cellular proliferation.
This registry study will be conducted in Europe, the US, and select other countries approved by their regulatory agency.
This registry study was initiated as a combined retrospective and prospective data collection effort. After the acquisition of LumiThera by Alcon Research, LLC in September 2025, the study was amended to prospectively collect data from U.S. sites starting in July 2026.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
In this multi-center registry study, each qualifying eye will or will have been treated with the Valeda Light Delivery System for a total of nine short, non-invasive treatments over a three-to-five-week period and retreated every four to six months for a total of up to six rounds of treatment, as determined by the investigator.
Participants are considered to have completed the study if they complete at least one full treatment round with Optical Coherence Tomography (OCT) imaging collected post treatment. Participation may last up to 31 months, or as determined by the Investigator as the duration between treatment rounds and number of treatment rounds may vary by participant based on the progression of the disease as determined by the Investigator.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Alcon Call Center
- Telefoonnummer: 1-888-451-3937
- E-mail: alcon.medinfo@alcon.com
Studie Locaties
-
-
-
Oslo, Noorwegen, 0366
- Actief, niet wervend
- Institutt for Oyehelse
-
-
-
-
California
-
Beverly Hills, California, Verenigde Staten, 90211
- Nog niet aan het werven
- Retina Vitreous Associates Medical Group
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45242
- Nog niet aan het werven
- Cincinnati Eye Institute
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29414
- Nog niet aan het werven
- Carolina Eyecare Physicians
-
-
Texas
-
McAllen, Texas, Verenigde Staten, 78503
- Werving
- Valley Retina Institute
-
-
Washington
-
Silverdale, Washington, Verenigde Staten, 98383
- Nog niet aan het werven
- Pacific Northwest Retina
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
The patient population for this study will consist of a target of at least 25 male and female participants per site of any ethnic background and with a diagnosis of dry AMD by the Investigator or confirmed by the Investigator. The participant must meet all the inclusion criteria, have none of the exclusion criteria, and give their written Informed Consent to participate in this clinical study.
Only if the participant is interested in participating, s/he would be given the option to sign the study consent and start the study procedures, or if retrospectively signing the informed consent form, have their data used in the study.
Beschrijving
Inclusion Criteria:
- Diagnosis or confirmation of diagnosis of dry AMD disease by Investigator;
- Able to communicate well with the Investigator and able to understand and comply with the requirements of the study;
- Informed of the nature of this study and has provided written, informed consent; (participants enrolled retrospectively will need to be contacted and sign an informed consent form prior to their data being used).
Exclusion Criteria:
- US Sites Only: Center-involving geographic atrophy;
- Neovascular maculopathy;
- Use of any photosensitizing agent (e.g. topicals, injectables) activated by the Valeda Light Deliver System within 30 days prior to treatment without consulting participant's physician;
- Known photosensitivity to yellow light, red light, or near infrared radiation (NIR), or has a history of light activated central nervous system disorders (e.g. epilepsy, migraine);
- In the opinion of the Investigator, is unlikely to comply with the study protocol or has a history or current evidence of any condition that, in the opinion of the investigator, might interfere with the participant's involvement in the trial, or is not in the best interest of the participant.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: CASE_ONLY
- Tijdsperspectieven: OTHER
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Photobiomodulation (PBM)
Two alternating and sequential treatments with the Valeda Light Delivery System of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds, followed by 660 nm for 90 seconds, or a total of 180 seconds |
FDA-approved, multi-wavelength light delivery system for providing a pre-set treatment of pulsed light in 3 distinct wavelengths (PBM) to the participant's eye and retinal tissue through the open and closed eyelid. The Valeda Light Delivery System is a CE Marked Class IIa device in Europe (Certificate # CE 653115) and a Class 2 device in the United States (DEN230083). |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Visual Acuity from Baseline at each Treatment Visit
Tijdsspanne: Baseline (Day 0) pre-treatment; up to Month 31/exit
|
Visual acuity will be assessed prior to any PBM treatment (baseline) and at each treatment visit after PBM was delivered. |
Baseline (Day 0) pre-treatment; up to Month 31/exit
|
|
Number of Adverse Events Associated with PBM Treatment
Tijdsspanne: Up to Month 31/exit
|
The number of adverse events associated with PBM treatment will be reported. |
Up to Month 31/exit
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Sr. Principal Clinical Trial Operations, Surgical, Alcon Research, LLC
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- CSP006
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .